Skip to Content


In the US, Adalimumab (adalimumab systemic) is a member of the following drug classes: antirheumatics, TNF alfa inhibitors and is used to treat Ankylosing Spondylitis, Behcet's Disease, Crohn's Disease, Crohn's Disease - Acute, Crohn's Disease - Maintenance, Hidradenitis Suppurativa, Juvenile Idiopathic Arthritis, Plaque Psoriasis, Psoriasis, Psoriatic Arthritis, Reiter's Syndrome, Rheumatoid Arthritis, Sarcoidosis, Spondyloarthritis and Ulcerative Colitis.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories


Anti-inflammatory agent

Disease-modifying antirheumatic drug, DMARD

Monoclonal antibody

Tumor necrosis factor alpha (TNF-α) inhibitor

Chemical Name

Immunoglobulin G 1 (human monoclonal D2E7 heavy chain anti-human tumor necrosis factor), disulfide with human monoclonal D2E7κ-chain, dimer (WHO )

Foreign Names

  • Adalimumabum (Latin)
  • Adalimumab (German)
  • Adalimumab (French)
  • Adalimumab (Spanish)

Generic Names

Brand Names

  • Humira
    Abbott, Argentina; Abbott, China; Abbott, Czech Republic; Abbott, Ecuador; Abbott, Egypt; Abbott, Italy; Abbott, Oman; Abbott, Peru; Abbott, Romania; Abbott, Serbia; Abbott, Russian Federation; Abbott, Slovakia; Abbott, Tunisia; Abbott, Taiwan; Abbott, Venezuela; Abbott, South Africa; Abbott Laboratories, Lithuania; Abbott Laboratories de Chile, Chile; AbbVie, Austria; AbbVie, Australia; AbbVie, Belgium; AbbVie, Canada; AbbVie, Switzerland; AbbVie, Germany; AbbVie, Denmark; AbbVie, France; AbbVie, United Kingdom; AbbVie, Greece; AbbVie, Hong Kong; AbbVie, Croatia (Hrvatska); AbbVie, Hungary; AbbVie, Ireland; AbbVie, Japan; AbbVie, South Korea; AbbVie, Latvia; AbbVie, Netherlands; AbbVie, Norway; AbbVie, New Zealand; AbbVie, Sweden; AbbVie, Singapore; AbbVie, Turkey; AbbVie, United States; AbbVie A/S, Iceland; ABBVIE BIOPHARMACEUTICALS, Israel; Abbvie Farmacéuticos, Mexico; AbbVie Inc., Bosnia & Herzegowina; AbbVie Polska, Poland; Vetter Pharma, Lebanon
  • Humira (pediatric)
    AbbVie, United Kingdom
  • Humira Kinder (pediatric)
    AbbVie, Austria
  • Humira Pediatrico (pediatric)
    Abbvie, Spain
  • Humira Pédiatrique (pediatric)
    AbbVie, France


BANBritish Approved Name
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.